Test Price
2,800 AEDโ Home Collection Available
DLX3 Gene Sequencing Test for Amelogenesis Imperfecta Type 4 | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Comprehensive DLX3 Genetic Analysis
- โ99.9% Analytical Sensitivity โ ISO-accredited NGS assay covering all coding exons of DLX3.
- โVIP Mobile Phlebotomy โ Hospital-grade, temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- โPost-Test Genetic Counselling โ Same-day telephonic result interpretation by a board-certified Consultant Medical Geneticist.
- โInsurance & Billing Support โ Direct billing verification and insurance reimbursement assistance via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The DLX3 gene provides instructions for a transcription factor critical to enamel formation and bone development. Pathogenic variants in DLX3 lead to Amelogenesis Imperfecta Type 4 (AI4) and Tricho-Dento-Osseous (TDO) syndrome. This Next-Generation Sequencing (NGS) assay provides comprehensive coverage of all coding exons and intron-exon boundaries, delivering definitive molecular diagnosis for hereditary enamel defects.
| Feature | Our DLX3 NGS Test | Standard Sanger Sequencing |
|---|---|---|
| Detection Rate | โฅ99.9% analytical sensitivity, full exon coverage including CNVs | ~97% sensitivity, limited to known hotspots, no CNV detection |
| Methodology | Next Generation Sequencing (Illuminaยฎ Platform) | Bidirectional Sanger Capillary Electrophoresis |
| Turnaround Time | 3 โ 4 weeks | 4 โ 6 weeks |
| Sample Flexibility | Whole blood, extracted DNA, dried FTA card, buccal swab | Whole blood only |
| Regulatory Approval | DHA/MOHAP approved, ISO 9001:2015 certified | May lack specific UAE accreditation |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specialist, I routinely evaluate families impacted by ectodermal dysplasias. The DLX3 NGS test offers a precise molecular anchor for diagnosing AI4 and TDO syndrome. However, genetic results must always be integrated with a full clinical and family history assessment. A multidisciplinary approach involving dental, dermatological, and genetic counselling services is essential for comprehensive patient care."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403)
Medication & Treatment Advisory
Do not discontinue or modify any prescribed dental or medical treatments without consulting your primary healthcare provider. This genetic test provides diagnostic information and is not a substitute for active clinical management.
Exclusion Criteria & Clinical Red Flags
- Exclusion Criteria: Allogenic blood transfusion within the last 8 weeks (buccal swab alternative available). Incomplete clinical history questionnaire.
- Clinical Red Flags: Acute dental abscess, facial cellulitis, unexplained bone pain, or sudden vision changes require immediate emergency medical evaluation. This test is strictly for elective genetic diagnosis and does not address acute symptomatic events.
Patient FAQ & Clinical Guidance
1. What is the DLX3 gene test for Amelogenesis Imperfecta Type 4?
This advanced NGS test screens the DLX3 gene for pathogenic variants causing Amelogenesis Imperfecta Type IV (AI4) and Tricho-Dento-Osseous (TDO) syndrome. It analyzes all coding exons to detect single nucleotide variants, small insertions or deletions, and copy number changes, providing a conclusive molecular diagnosis for hereditary enamel defects.
2. How should I prepare for the DLX3 genetic test?
No special preparation, fasting, or medication changes are required. A genetic counsellor will guide you through a detailed clinical history and family pedigree questionnaire before sample collection. This ensures accurate variant interpretation and comprehensive risk assessment.
3. When will I receive my results and how are they delivered?
Results are typically available within 3 to 4 weeks. They are delivered through a secure, encrypted online portal. A dedicated teleconsultation with our board-certified geneticist is scheduled to explain the findings and discuss the clinical implications and management plan.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Regulatory Compliance
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted with AES-256, securely stored, and processed under ISO 9001:2015 certified protocols. Patient consent procedures align with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring full transparency and ethical compliance.
Your genetic information is never shared with third parties without your explicit written consent. We adhere to the highest standards of medical confidentiality and data security mandated by UAE law.
Clinical & Logistical Metadata
| Test Name | DLX3 Gene Sequencing (Amelogenesis Imperfecta Type 4 / TDO Syndrome) |
| Price (AED) | 2,800 |
| Turnaround Time | 21 - 28 Days (3 - 4 Weeks) |
| Sample Type / Matrix | Whole Blood (EDTA) or Extracted DNA; Buccal Swab if transfusion contraindication |
| Methodology Used | Next-Generation Sequencing (NGS) - Illuminaยฎ Platform, Full Exon Coverage |
| ICD-10-CM Code | K00.5 (Hereditary disturbances in tooth structure, not elsewhere classified) |
| LOINC Code | 88715-7 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians